Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Nov 19.
Published in final edited form as: J Org Chem. 2010 Nov 19;75(22):7939–7941.

Two-Steps Hantzsch Based Macrocyclization Approach for the Synthesis of Thiazole Containing Cyclopeptides

Adel Nefzi 1,*, Sergey Arutyunyan 1, Jason E Fenwick 1
PMCID: PMC2989683  NIHMSID: NIHMS249603  PMID: 21113437

Abstract

Macrocyclization via an efficient high-yielding solid-phase intramolecular thioalkylation reaction is described. The reaction of S-nucleophiles with newly generated N-terminal 4-chloromethyl thiazoles led to the desired macrocyclization products 5 in high purities and good overall yields.

Introduction

Conformational constraint by cyclization is a common approach used to restrict the flexibility of peptides and therefore is a valuable approach to study topographical requirements of receptors.1 Cyclization of peptides can provide potent and selective ligands for receptors when appropriate conformational constraints are incorporated.1 Furthermore cyclic peptides are often more stable to peptidases, and therefore they can have improved pharmacokinetic profiles and serve as promising lead compounds for further development.2 Macrocycles are known for their broad range of activities including antitumor activities and antibiotic activities such as the structurally complex vancomycin family.3 Reported approaches on the solid-phase synthesis of macrocyclic compounds include intramolecular nucleophilic substitutions,4,1a intramolecular amide formations,5,1c disulfide formations,6 intramolecular Suzuki reactions,7 ring closing metathesis reactions8 and SNAr displacement reactions.9 Of particular interest, thioalkylation reactions offer a facile and versatile approach to the synthesis of cyclic peptides.4,10 Examples of described macrocyclizations via thioalkylation include the reaction of the thiol group of a C-terminal cysteine with N-terminal acetyl bromide or N-terminal benzyl bromide.4,10 A conceptually different approach, wherein thioalkylation proceeds via Michael addition of a thiolate anion to an α,β-unsaturated ester, has been reported for the synthesis of cyclic thioether dipeptides. 11

Results and Discussion

Herein, we describe an innovative thioalkylation approach toward the generation of macrocyclic peptides following the intramolecular nucleophilic substitution (SN2) of N-terminus 4-chloro methyl thiazole peptides with the thiol group of cysteine. The final products are not entirely peptidic and the described newly generated macrocyclic compounds contain the thiazole ring, a pharmacophore present in many natural and synthetic products with a wide range of pharmacological activities that can be well illustrated by the large numbers of naturally occurring thiazole containing macrocyclic compounds 12 and drugs in the market containing this function group.13

We have shown the feasibility of the proposed approach by the parallel synthesis of different thiazole containing macrocyclic peptides. Starting from resin-bound orthogonally protected Fmoc-Cys-(Trt)-OH 1, the thiomethyl thiazolyl macrocyclic peptidomimetics 5 were synthesized following stepwise Fmoc deprotection14 and standard repetitive Fmoc-amino-acid couplings yielding the linear tripeptide 2. The resulting N-terminal free amine was treated with Fmoc-isothiocyanate. Following Fmoc deprotection, the thioureas were treated with 1,3-dichloroacetone to afford following Hantzsch’s cyclocondensation15 the resulting resin-bound chloro methyl thiazolyl peptide 4. The Trt group was deprotected in the presence of 5%TFA in DCM and the resin was treated with a solution of CsOH-H2O in DMF to undergo an SN2 intramolecular cyclization. The resin was cleaved with HF/anisole and the desired thiazolyl thioether cyclic peptides 5 were obtained in good yield and high purity. An Ellman test for free thiols was performed on all samples. No free thiol was present in the crude material. The identity of the final products was confirmed by LC-MS and NMR spectroscopy.

Many reagents and techniques have been developed to facilitate the synthesis of cyclic peptides, for which the yield-limiting step is generally the cyclization reaction. Particularly, the cyclization of tetra-, penta-, and hexapeptides in the all L-configuration can be problematic, especially in the absence of beta-turn promoting structures such as glycine, proline, or a D-amino acid.16 Using the approach outlined in scheme 1, we first tested our approach by performing the parallel synthesis of various thiazole containing cyclic tetrapeptides and pentapeptides from all L-amino acids (Figure 1).

Scheme 1.

Scheme 1

Reagents and conditions: (a) Solid phase peptide synthesis using Fmoc Chemistry; (b) FmocNCS (6 equiv) in DMF (0.3 M), RT, overnight; (c) 20% piperidine/DMF; (d) 1,3-dichloroacetone (10 equiv) in DMF (0.3 M), 70°C, overnight; (e) TFA/(But)3SiH/DCM (5:5:90), 30 min; (f) Cs2CO3 in DMF overnight; (g) HF/anisole, 0°C, 90 min.

Figure 1.

Figure 1

We selected different amino acids for each of the position of diversities R1, R2 and R3 for the synthesis of eleven tetrapeptides (5a-5k). Thus, we choose Phe, Tyr, Ser and Val for the position R1, Phe, Tyr and Pro for the position R2 and Tyr, Pro and Lys for the position R3. Similarly, we selected three amino acids for each of the position of diversities R1 (Tyr, Phe, Asp), R3 (Tyr, Pro, Arg) and two amino acids for each of the position of diversities R2 ( Tyr, Gly) and and R4 (Tyr, Pro) for the synthesis of nine pentapeptides (5l-5t). As shown in table 1, high purities were obtained for all compounds. In all cases, the intramolecular thioalkylation reaction led to the desired cyclic monomers with negligible traces of dimerization. The NMR data show a clear singlet at 6.4 ppm which is specific to the proton on C-5 of the aminothiazole ring. The presented methodology is not limited to cyclic tetrapeptides and pentapeptides. It was successfully used for the synthesis of cyclic hexapeptides 5u-5v and heptapeptide 5w.

Table 1.

Synthesis of thiazole containing cyclic tetrapeptides and pentapeptides

graphic file with name nihms-249603-t0003.jpg
Entry Peptide Puritya (%) Yieldb
5a Tyr-Phe-Phe 88 45
5b Pro-Phe-Phe 85 38
5c Tyr-Tyr-Phe 88 43
5d Pro-Tyr-Phe 89 41
5e Tyr-Phe-Tyr 87 40
5f Pro-Phe-Tyr 76 29
5g Tyr-Tyr-Tyr 83 38
5h Pro-Tyr-Tyr 89 46
5i Tyr-Pro-Ser 85 47
5j Tyr-Tyr-Ser 86 43
5k Lys-Tyr-Val 82 40
5l Tyr-Tyr-Tyr-Phe 86 38
5m Pro-Tyr-Tyr-Phe 90 39
5n Tyr-Pro-Tyr-Phe 80 31
5o Pro-Pro-Tyr-Phe 83 37
5p Tyr-Tyr-Tyr-Tyr 82 31
5q Pro-Tyr-Tyr-Tyr 85 35
5r Tyr-Pro-Tyr-Tyr 80 34
5s Pro-Pro-Tyr-Tyr 78 35
5t Tyr-Arg-Gly-Asp 84 43
5u Arg-Gly-Asp-Tyr-Tyr 82 40
5v Phe-Tyr-Val-Ser-Ala 80 37
5w Phe-Ala-Pro-Tyr-Ser-Phe 82 39
a

Purity of crude products: The products were run on a Vydac column, gradients 5 to 95% formic acid in ACN in 7 min. The purity was estimated on analytical traces at λ= 214 nm and 254 nm.

b

The yields are based on the weight of purified products and are relatives to the initial loading of the resin (The purity of the purified compounds is higher than 95% for all the compounds).

Conclusion

We presented a new method for macrocyclization reaction via thioalkylation. The reaction of S-nucleophiles with newly generated N-terminal 4-chloromethyl thiazoles led to the desired macrocyclization products in high purities and good overall yields. The presented approach can be extended toward the synthesis of macrocyclic libraries where the cysteine residue can be placed anywhere in the peptide sequence, allowing for extension of the peptide beyond the cyclic link. As part of our drug discovery program, we are in the process of preparing a variety of thiazole containing macrocyclic libraries. The synthesis and the screening results will be reported elsewhere.

Experimental Section

Synthesis of resin-bound cysteine

A 100 mg sample of p-methylbenzhydrylamine hydrochloride (MBHA·HCl) resin (CHEM-IMPEX INTERNATIONAL 1.15 mequiv/g, 100-200 mesh, 1% DVB) was contained within a sealed polypropylene mesh bag. 23 bags (23 × 100 mg resin, 2.64 mmol) were put in a polyethylene bottle. Following the neutralization of resin with 500 ml of 5% diisopropylethylamine (DIEA) in dichloromethane (DCM), L-Fmoc-Cys(Trt)-OH (3 eq, 4.64 g, 7.93 mmol) was coupled using the conventional reagents hydroxybenzotriazole (HOBt, 1.07 g, 7.93 mmol) and diisopropylcarbodiimide (DIC, 1.16 ml, 7.93 mmol) in 300 ml anhydrous DMF overnight at room temperature. Completion of the coupling was monitored by the ninhydrin test.

General procedure for the solid-phase synthesis of resin-bound linear cyclic peptide 5a

One bag of resin 1 (100 mg, 0.115 mmol) was put into a small polyethylene bottle and the Fmoc group was deprotected with 15 ml 20% piperidine in DMF (2×10min). The resin was then washed with 15 ml DMF (3×) and 15 ml DCM (3×). L-Fmoc-Phe-OH (6 equiv, 0.267 g, 11.04 mmol) was coupled in the presence of hydroxybenzotriazole (HOBt, 6 equiv, 0.094 g, 11.04 mmol) and diisopropylcarbodiimide (DIC, 6 equiv, 0.101 ml, 11.04 mmol) in 15 ml anhydrous DMF for 2h at room temperature. The resin-bound dipeptide was washed with DMF (3×) and DCM (3×). Completion of the coupling was monitored by the ninhydrin test. The Fmoc group was deprotected with 15 ml 20% piperidine in DMF (2×10min) and followed by the coupling of L-Fmoc-Phe-OH (6 equiv, 0.267 g, 11.04 mmol) using the same reaction conditions. The Fmoc group was deprotected and the resin-bound tripeptide was coupled to L-Fmoc-Tyr(tBu)-OH in the same conditions to yield following Fmoc deprotection the corresponding resin-bound protected linear peptide 2a.

The resulting N-terminal free amine of resin-bound linear peptide 2a was treated with Fmoc-isothiocyanate (6 equiv, 0.193 g, 11.04 mmol) in 15 ml DMF anhydrous overnight at room temperature. Following Fmoc deprotection with a solution of 20% piperidine in DMF, the resin-bound N-terminal thiourea was treated with 1,3-dichloroacetone (10 equiv, 0.145 g, 18.4 mmol) in DMF anhydrous overnight at 70 °C to afford following Hantzsch’s cyclocondensation the resulting resin-bound chloro methyl thiazolyl peptide 4a. The Trt group was deprotected in the presence of TFA/(But)3SiH/DCM (5:5:90) for 30 min. The resin was washed with DCM (5×) and DIEA/DCM (5:95) and was treated overnight with a solution of Cs2CO3 (10 eq, 0.325 g) in 15 ml DMF at room temperature to undergo an SN2 intramolecular thialkylation. The resin was cleaved with HF/anisole for 90 min at 0 °C, and the desired thiazolyl thioether cyclic peptides 5a was obtained following extraction with 95% acetic acid in water and lyophilization as a white powder (61.9 mg). The cyclic peptides 5a was purified by preparative reverse-phase HPLC.

Supplementary Material

1_si_001
2_si_002

Acknowledgment

The authors would like to thank the State of Florida Funding, NIH (1R03DA025850-01A1, Nefzi), NIH (5P41GM081261-03 , Houghten) and NIH (3P41GM079590-03S1, Houghten) for their financial support.

Footnotes

Supporting Information Available: Experimental details and analytical data including: NMR-data, NMR-spectra, HPLC chromatograms and mass spectra for all reported cyclic peptides. HPLC and LC-MS of additional cyclic tetrapeptides and pentapeptides not reported in the paper. This material is available free of charge via the Internet at http://pubs.acs.org.

References

  • (1).(a) Lambert JN, Mitchell JP, Roberts KD. J. Chem. Soc., Perkin Trans. 1. 2001:471–484. [Google Scholar]; (b) Hruby VJ, Balse PM. Curr. Med. Chem. 2000;7:945–970. doi: 10.2174/0929867003374499. [DOI] [PubMed] [Google Scholar]; (c) Hruby VJ. Nature Reviews Drug Discovery. 2002;1:847–858. doi: 10.1038/nrd939. [DOI] [PubMed] [Google Scholar]; (d) Jones RM, Bulaj G. Curr. Opin. Drug Discovery Dev. 2000;3:141–154. [PubMed] [Google Scholar]; (e) Vagner J, Qu H, Hruby VJ. Current Opinion in Chemical Biology. 2008;12:292–296. doi: 10.1016/j.cbpa.2008.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]; (f) Hruby VJ. Life Sci. 1982;31:189–199. doi: 10.1016/0024-3205(82)90578-1. [DOI] [PubMed] [Google Scholar]
  • (2).(a) Schiller PW. Handb. Exp. Pharmacol. 1993;104:681–710. [Google Scholar]; (b) Fang W, Cui Y, Murray TF, Aldrich JV. J. Med. Chem. 2009;52:5619–5625. doi: 10.1021/jm900577k. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Berezowska I, Lemieux C, Chung NN, Wilkes BC, Schiller PW. Chem Biol Drug Des. 2009;74:329–334. doi: 10.1111/j.1747-0285.2009.00867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Purington LC, Pogozheva ID, Traynor JR, Mosberg HI. J. Med. Chem. 2009;52:7724–7731. doi: 10.1021/jm9007483. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Mollica A, Guardiani G, Davis P, Ma S, Porreca F, Lai J, Manina L, Sobolev AP, Hruby VJ. J. Med. Chem. 2007;50:3138–3142. doi: 10.1021/jm061048b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (3).(a) Driggers EM, Hale SP, Lee J, Terrett NK. Nature Reviews. Drug Discovery. 2008;7:608–624. doi: 10.1038/nrd2590. [DOI] [PubMed] [Google Scholar]; (b) Blout ER. Biopolymers. 1981;20:1901–1912. [Google Scholar]
  • (4).(a) Feng Y, Pattarawarapan M, Wang Z, Burgess K. Org Lett. 1999;1:121. doi: 10.1021/ol990597r. [DOI] [PubMed] [Google Scholar]; (b) Roberts KD, Lambert JN, Ede NJ, Bray AM. J. Pep. Sci. 2006;12:525–532. doi: 10.1002/psc.761. [DOI] [PubMed] [Google Scholar]; (c) Ede NJ, Poberts KD. J. Pep. Sci. 2007;13:811–821. doi: 10.1002/psc.904. [DOI] [PubMed] [Google Scholar]
  • (5).(a) Dixon MJ, Nathubhai A, Andersen OA, van Aalten DMF, Eggleston IM. Org. Biomol. Chem. 2009;7:259–268. doi: 10.1039/b815077j. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Romanovskis P, Spatola AF. J. Pep. Res. 1998;52:356. doi: 10.1111/j.1399-3011.1998.tb00660.x. [DOI] [PubMed] [Google Scholar]; (d) Alsina J, Jensen KJ, Albericio F, Barany G. Chem. Eur. J. 1999;5:2787–2795. [Google Scholar]
  • (6).(a) Craik DJ, Cemazar M, Daly NL. Current Opinion in Drug Discovery & Development. 2007;10:176–184. [PubMed] [Google Scholar]; (b) Pons M, Albericio F, Royo M, Giralt E. Synlett. 2000;2:172–181. [Google Scholar]; (c) Annis I, Chen L, Barany G. J. Am. Chem. Soc. 1998;120:7226–7238. [Google Scholar]
  • (7).(a) Feliu L, Planas M. Int J Pept Res Ther. 2005;11:53–97. [Google Scholar]; (b) Li P, Roller PP, Xu J. Curr. Org. Chem. 2002;6:411–440. [Google Scholar]; (c) Kaiser M, Siciliano C, Assfalg-Machleidt I, Groll M, Milbradt AG, Moroder L. Org. Lett. 2003;5:3435–3437. doi: 10.1021/ol035178f. [DOI] [PubMed] [Google Scholar]
  • (8).(a) Blackwell HE, Grubbs RH. Angew. Chem. Int. Ed. 1998;37:3281–3284. doi: 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]; (b) Reichwein JF, Versluis C, Liskamp RMJ. J. Org. Chem. 2000;65:6187–6195. doi: 10.1021/jo000759t. [DOI] [PubMed] [Google Scholar]; (c) Boyle TP, Bremner JB, Coates J, Deadman J, Keller PA, Pyne SG, Rhodes DI. Tetrahedron. 2008;64:11270–11290. [Google Scholar]
  • (9).(a) Feng Y, Burgess K. Chem. Eur. J. 1999;5:3261–3265. [Google Scholar]; b) Wang Z, Jin S, Feng Y, Burgess K. Chem. Eur. J . 1999;5:3273–3277. [Google Scholar]; (c) Grieco P, Cai M, Liu L, Mayorov A, Chandler K, Trivedi D, Lin G, Campiglia P, Novellino E, Hruby VJ. J. Med. Chem. 2008;51:2701–2707. doi: 10.1021/jm701181n. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Derbal S, Ghedira K, Nefzi A. Tet Lett. 2010;51:3607. doi: 10.1016/j.bmcl.2010.08.015. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Giulianotti M, Nefzi A. Tet Lett. 2003;44:5307–5309. [Google Scholar]
  • (10).(a) Jung G. Angew. Chem. Int. Ed. Engl. 1991;30:1051–1068. [Google Scholar]; (b) Campiglia P, Gomez-Monterrey I, Longobardo L, Lama T, Novellino E, Grieco P. Tet Lett. 2004;45:1453–1456. [Google Scholar]; (c) Jack RW, Jung G. Curr. Opin. Chem. Biol. 2000;4:310–317. doi: 10.1016/s1367-5931(00)00094-6. [DOI] [PubMed] [Google Scholar]; (d) Kaiser D, Jack RW, Jung G. Pure Appl. Chem. 1998;70:97–104. [Google Scholar]
  • (11).Crescenza A, Botta M, Corelli F, Santini A, Tafi A. J. Org. Chem. 1999;64:3019–3025. doi: 10.1021/jo981425v. [DOI] [PubMed] [Google Scholar]
  • (12).(a) Jin Z. Nat. Prod. Rep. 2003;20:584–605. doi: 10.1039/b304142p. [DOI] [PubMed] [Google Scholar]; (b) Bertram A, Blake AJ, de Turiso F, Hannam JS, Jolliffe KA, Pattenden G, Skae M. Tetrahedron. 2003;59:6979–6990. [Google Scholar]; (c) Jin Z. Nat. Prod. Rep. 2006;23:464–496. doi: 10.1039/b502166a. [DOI] [PubMed] [Google Scholar]
  • (13).(a) Vinicius M, Souza ND. Journal of Sulfur Chemistry. 2005;26:429–449. [Google Scholar]; (b) Rezanka T, Sobotka M, Spizek J, Sigler K. Anti-Infective Agents in Medicinal Chemistry. 2006;5:187–224. [Google Scholar]; (c) Sanfilippo PJ, Jetter MC, Cordova R, Noe RA, Chourmousis E, Lau CY, Wang E. J. Med. Chem. 1995;38:1057–1059. doi: 10.1021/jm00007a002. [DOI] [PubMed] [Google Scholar]; (d) Suzuki S, Yonezawa Y, Shin C. Chem. Lett. 2004;33:815. [Google Scholar]
  • (14).Fields GB, Noble RL. Int. J. Peptide Protein Res. 1990;35:161–214. doi: 10.1111/j.1399-3011.1990.tb00939.x. [DOI] [PubMed] [Google Scholar]
  • (15).(a) Hantzsch AR, Weber JH. Ber. 1887;20:3118–3132. [Google Scholar]; (b) Garcia-Egido E, Wong SYF, Warrington BH. Lab Chip. 2002;2:31–33. doi: 10.1039/b109360f. [DOI] [PubMed] [Google Scholar]; (c) Lin PY, Hou RS, Wang HM, Kang IJ, Chen LC. Journal of the Chinese Chemical Society. 2009;56:455–458. [Google Scholar]; (d) Kearney PC, Fernandez M, Flygare JA. J. Org. Chem. 1998;63:196–200. doi: 10.1021/jo971542a. [DOI] [PubMed] [Google Scholar]; (e) Arutyunyan S, Nefzi A. J. Com. Chem. 2010;12:315–317. doi: 10.1021/cc9001907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (16).(a) Rose GD, Gierasch LM, Smith JA. In: Advances in Protein Chemistry. Anfinsen CB, Edsall JT, Richards FM, editors. Vol. 37. Academic; Orlando, FL: 1985. pp. 1–109. [DOI] [PubMed] [Google Scholar]; (b) Olson GL, Bolin DR, Bonner MP, Bos M, Cook CM, Fry DC, Graves BJ, Hatada M, Hill DE, Kahn M, Madison VS, Rusiecki VK, Sarabu R, Sepinwall J, Vincent GP, Voss ME. J. Med. Chem. 1993;36:3039–3046. doi: 10.1021/jm00073a001. [DOI] [PubMed] [Google Scholar]; (e) Mueller G. Angew. Chem., Int. Ed. 1997;35:2767–2771. [Google Scholar]; (f) MacDonald M, Aube J. Curr. Org. Chem. 2001;5:417–421. [Google Scholar]; (g) Hruby VJ. Nat. Rev. Drug Discovery. 2002;1:847. doi: 10.1038/nrd939. [DOI] [PubMed] [Google Scholar]; (h) Suat Kee K, Jois SDS. Curr. Pharm. Des. 2003;9:1209–1212. doi: 10.2174/1381612033454900. [DOI] [PubMed] [Google Scholar]; (i) Zhang J, Xiong C, Ying J, Wang W, Hruby V. J. Org. Lett. 2003;5:3115–3119. doi: 10.1021/ol0351347. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001
2_si_002

RESOURCES